Furthermore, the MTT assay demonstrated that either CP-10 or BSJ-03-123 combined with lenvatinib synergistically suppressed the growth of lenvatinib-resistant PLC/PRF/5 and Huh7 cells and high CDK6-expressing HCC cells (Fig. 4e, Supplementary Fig. 6b). Here, CDK6 is linked to hepatocellular carcinoma.